HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions
详细信息 查看全文
- 作者：Junko Tanuma ; Mamoru Fujiwara ; Katsuji Teruya ; Saori Matsuoka ; Hikaru Yamanaka ; Hiroyuki Gatanaga ; Natsuo Tachikawa ; Yoshimi Kikuchi ; Masafumi Takiguchi ; Shinichi Oka
- 关键词：Structured treatment interruptions ; Cytotoxic T lymphocyte ; HLA-A*2402 ; Escape variant
- 刊名：Microbes and Infection
- 出版年：2008
- 出版时间：May 2008
- 年：2008
- 卷：10
- 期：6
- 页码：689-698
- 全文大小：1072 K
文摘
Five CTL clones specific for the A*02 restricted peptide epitope of TAA Mage-3, designated M3-271, were studied. All these clones were able to recognize peptide M3-271 when presented by BLCLs expressing A*0201, A*0206 and A*0209. In contrast, peptide pulsed BLCLs carrying A*0202 or A*0205 were recognized by none of the clones. As determined by in vitro peptide binding studies, this was not due to a lack of binding ability of peptide M3-271 to these two A*02 subtypes. Finally, three or two of the five clones analyzed were able to recognize peptide pulsed BLCLs carrying A*0204 or A*0207, respectively.
A CTL line specific for the dominant, A*02 restricted epitope of TAA Melan-A/MART-1, designated MT27-35, was able to lyse peptide pulsed BLCLs expressing all A*02 subtypes analyzed except for A*0207. This may be due to a lack of binding activity of MT27-35 to A*0207 since others have shown that polyalanine peptides carrying the same P2/P9 anchor residues as MT27-35 were unable to bind to A*0207 while they could readily bind to the other A*02 subtypes tested in this study.